HARROW INC (HROW)
Health Care · NASDAQ
Harrow Inc is a leading North American provider of ophthalmic disease management solutions, offering a comprehensive portfolio of FDA-approved eye care medications and products for conditions including dry eye disease,…
What HARROW INC does
Harrow Inc is a leading North American provider of ophthalmic disease management solutions, offering a comprehensive portfolio of FDA-approved eye care medications and products for conditions including dry eye disease, wet age-related macular degeneration, cataracts, glaucoma, and other ocular surface and retinal diseases. The company markets branded pharmaceutical products to eyecare professionals and has expanded through acquisitions and licensing transactions to serve both U.S. and Canadian markets. Harrow combines clinical innovation with operational discipline to deliver safe, effective, and accessible ophthalmic treatments.
Themes: ["ophthalmic pharmaceuticals / eye care","dry eye disease","wet age-related macular degeneration (AMD)","glaucoma","biosimilar eye medications","retinal disease / diabetic retinopathy","ophthalmic steroids and anti-inflammatory","antibiotic and antifungal eye drops"]
Fundamentals
- Price$42.93 as of 2026-07-09 close
- Market cap$1.6B as of 2026-07-10
- 1-year return+35.6% as of 2026-07-09 close
- Net margin-5.6% as of 2026-07-10
- Gross margin+74.1% as of 2026-07-10
- ROE-33.7% as of 2026-07-10
- Debt / equity10.18 as of 2026-07-10
- Revenue growth (YoY)+26.2% as of 2026-07-10
- Revenue CAGR (3y)+45.4% SEC XBRL
- Beta0.23 as of 2026-07-10
Key risks (from latest filing)
["Company is unprofitable with negative net margin of -5.57% and accumulated deficit of $184.1M; reliance on new product launches (BYOOVIZ mid-2026, BYQLOVI mid-2026, OPUVIZ mid-2027) to drive growth and reach profitability.","High debt burden with $292.1M in notes payable and significant interest expense ($5.5M in Q1 2026); biosimilar product launches face reimbursement and competition risks from established branded rivals.","Revenue declined 7.6% YoY in Q1 2026 ($44.2M vs $47.8M) despite 26.22% growth claimed for full-year basis; operating expenses are growing (SG&A rose 6.7% and R&D nearly doubled) as the company scales to commercialize pipeline."]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.